CALGARY, Alta., Jan. 20, 2022 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX“or the”Society” (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a therapeutic pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David MacDonald to the position Chief Technology Officer (CTO). Dr. MacDonald has over 30 years of experience in drug development and leadership in the pharmaceutical and biotechnology fields, hitting critical value inflection milestones for these companies.
Dr. Allen Davidoff, CEO of XORTX, said, “We are delighted to welcome Dr. MacDonald to the management team and to a leadership role within the company. David brings to the team C-Suite leadership, extensive regulatory and clinical experience as well as a strong innovative technology background in drug development – qualities that align with clinical, regulatory and commercialization plans for the future.
Prior to XORTX, Dr. MacDonald served as CTO and then President of MSI Methylation Sciences Inc., a clinical-stage pharmaceutical (“MSI”) company. As CTO, David led R&D, pharmaceuticals and clinical development. Prior to his role at MSI, David served as President and CEO of Active Pass Pharmaceuticals. In addition, he has held leadership positions in several large and small pharmaceutical biotechnology companies where he was responsible for a wide range of technical departments and development stages spanning basic research, enabling IND studies, formulation, CMC, clinical trials, intellectual property. and regulatory submissions and inspections.
Dr. MacDonald is an inventor with over 20 issued patents worldwide and has published 14 manuscripts in peer-reviewed journals. He got his doctorate. in Chemistry from the University of Alberta, where his research focused on enzymology. https://www.linkedin.com/in/dmac36/.
In addition, the Company has issued a total of 127,500 options to purchase common shares of the Company to certain officers, employees and consultants pursuant to the Company’s stock option plan. The options are exercisable at a price of C$2.54 per common share and expire five years from the date of grant.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney injury and other acute organ injury associated with coronavirus/COVID infection -19 and XRx -225 is a preclinical stage program for type 2 diabetic nephropathy (T2DN). XORTX strives to advance its products in clinical development that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit uric acid production. At XORTX Therapeutics, we are dedicated to developing medicines to improve the quality of life and future health of patients. Additional information about XORTX Therapeutics is available at www.xortx.com.
The TSX Venture Exchange and the Nasdaq have neither approved nor disapproved of the contents of this press release. No stock exchange, securities commission or other regulatory authority has approved or disapproved of the information contained herein.